<DOC>
	<DOCNO>NCT01780389</DOCNO>
	<brief_summary>The current study examines effect milnacipran patient chronic persistent knee pain one year longer total knee arthroplasty ( TKA ) evaluate pain-relieving effect .</brief_summary>
	<brief_title>Open-label Milnacipran Persistent Knee Pain One Year After Total Knee Arthroplasty ( TKA )</brief_title>
	<detailed_description>The current study proposes collect pilot data utility open-label milnacipran treatment pain outcomes unfortunate group patient chronic persistent pain TKA . Among marketed serotonin norepinephrine reuptake inhibitor ( SNRIs ) , milnacipran unique property block serotonin norepinephrine reuptake equally . It plausible equipotent reuptake inhibition may confer great analgesic benefit compare agent , preclinical animal model milnacipran show superior effect ameliorate hyperalgesia allodynia compare antidepressant drug . Additionally , milnacipran inhibitory effect cytochrome P ( CYP ) 450 enzyme , bind affinity neurotransmitter receptor liable cause adverse event , simple pharmacokinetics .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>1 . Subject male female adult outpatient age 18 old time consent . 2 . Subject chronic persistent pain 1 year TKA without history new injury , infection , implant failure . 3 . Subject VAS &gt; = 40 mm screen baseline visit . 4 . Subject understanding , ability willingness fully comply study procedure restriction . 5 . Subject ability provide write , personally sign date informed consent participate study , accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) Guideline E6 applicable regulation , complete studyrelated procedure . 1 . Subjects unable complete assessment due language cognitive impairment 2 . Subjects history bipolar disorder psychosis confirm Mini International Neuropsychiatric Interview ( MINI ) . 3 . Subject currently ( history within last 6 month ) drug dependence substance abuse disorder accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision ( DSMIVTR ) criterion ( exclude nicotine ) . 4 . Subjects currently consider suicide risk , subject previously make suicide attempt prior history currently demonstrate active suicidal ideation . 5 . Subject clinically significant ECG clinically significant laboratory abnormality ( include positive urine drug screen ) Screening . 6 . Subject concurrent chronic acute illness , disability , condition might confound result safety assessment administer study might increase risk subject . Similarly , subject exclude additional condition ( ) Investigator 's opinion would prohibit subject completing study would best interest subject . This would include significant illness unstable medical condition could lead difficulty comply protocol . 7 . Subjects agree use adequate reliable contraception throughout study . 8 . Subject previously complete , discontinue withdrawn study . 9 . Subject take investigational drug take part clinical trial within 30 day prior Screening . 10 . Subjects treat antidepressant medication within 4 week screen visit ( 6 week fluoxetine ) . 11 . Subjects know sensitivity milnacipran . 12 . Subjects liver disease reduce liver function 13 . Subjects obstructive uropathy 14 . Subjects consume alcohol amount view Investigator contraindicate 15 . Subjects take monoamine oxidase inhibitor 16 . Subjects uncontrolled narrow angle glaucoma 17 . Subjects pregnant , may become pregnant , nurse 18 . Subjects seizure disorder 19 . Subjects bleed disorder use medication may cause bleeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Knee</keyword>
	<keyword>Pain</keyword>
	<keyword>Osteoarthritis</keyword>
</DOC>